Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9278806 | 0.95 | ALDH1A1 (0.90) | ALDH1A1TP53GAAKDM4ELMNA | |
| SCHEMBL11548243 | 0.90 | ALDH1A1 (0.81) | ALDH1A1TP53GAAKDM4ELMNA | |
| SCHEMBL13889021 | 0.90 | ALDH1A1 (0.81) | ALDH1A1TP53GAAKDM4ELMNA | |
| SCHEMBL412302 | 0.89 | ALDH1A1 (0.79) | ALDH1A1GAAKDM4ELMNAPKM | |
| SCHEMBL3913371 | 0.89 | ALDH1A1 (0.79) | ALDH1A1TP53GAAKDM4ELMNA | |
| SCHEMBL1287271 | 0.89 | ALDH1A1 (1.00) | ALDH1A1TP53GAATAAR1HSD17B10 | |
| SCHEMBL1287382 | 0.89 | TAAR1 (0.82) | ALDH1A1TP53GAAKDM4ELMNA | |
| SCHEMBL28808214 | 0.89 | ALDH1A1 (0.79) | ALDH1A1TP53GAAPOLBTAAR1 | |
| SCHEMBL4520992 | 0.87 | ALDH1A1 (0.77) | ALDH1A1TP53GAALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3517769 | 0.87 | ALDH1A1 (0.77) | ALDH1A1GAAKDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| CN-104969406-B | Electrolyte solution for electrochemical device and electrochemical device | 富士胶片和光纯药株式会社 | 2018-11-02 | — | — | CN | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| CN-104969406-A | Electrolyte solution for electrochemical device and electrochemical device | WAKO PURE CHEM IND LTD | 2015-10-07 | — | — | CN | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | ALDH1A1 1694/4885TP53 1452/4885GAA 746/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885TP53 648/4885GAA 3321/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | ALDH1A1 665/4885TP53 224/4885GAA 1320/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | ALDH1A1 897/4885TP53 282/4885GAA 1658/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | ALDH1A1 2597/4885TP53 545/4885GAA 3321/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ALDH1A1 2578/4885TP53 648/4885GAA 3321/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885TP53 648/4885GAA 3321/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ALDH1A1 2578/4885TP53 648/4885GAA 3321/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885TP53 358/4885GAA 3255/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | ALDH1A1 2597/4885TP53 545/4885GAA 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.